Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| KD | Kyndryl | $10.49 | -$13.01 | -55.36% | 646.3K | $5.4B | $10.11$44.20 |
| PLYX | Polaryx Therapeutics | $5.98 | -$2.93 | -32.88% | 72.2K | $422M | $2.51$48.91 |
| FLYE | Fly-E Group | $2.50 | -$0.96 | -27.75% | 7.4K | $5.6M | $2.50$161.80 |
| SMX | Smx (Security Matters) Public | $11.89 | -$3.94 | -24.89% | 2.5M | $138M | $3.12$9,134.28 |
| PFSA | Profusa | $3.29 | -$1.08 | -24.76% | 168.2K | $378M | $3.21$957.00 |
| HIMS | Hims & Hers Health | $17.53 | -$5.50 | -23.87% | 2.2M | $5.2B | $16.36$72.98 |
| RDIB | Reading International | $10.46 | -$3.00 | -22.29% | 22.9K | $306M | $5.81$17.40 |
| MNDY | Monday.com | $76.53 | -$21.47 | -21.91% | 267.2K | $5.0B | $73.01$342.64 |
| PGY | Pagaya Technologies | $15.01 | -$3.63 | -19.47% | 544.3K | $1.5B | $8.50$44.99 |
| SXTC | China Sxt Pharmaceuticals | $2.44 | -$0.56 | -18.67% | 4.2M | $2.6M | $2.41$1,176.00 |
| CLF | Cleveland-Cliffs | $12.02 | -$2.71 | -18.40% | 27.6M | $8.4B | $5.63$16.70 |
| MPAA | Motorcar Parts Of America | $10.80 | -$2.34 | -17.81% | 4.8K | $257M | $6.04$18.12 |
| ALX | Alexander's | $218.87 | -$36.20 | -14.19% | 2.4K | $1.3B | $189.05$260.84 |
| VHUB | VenHub Global | $4.19 | -$0.64 | -13.25% | 163.7K | $362M | $4.02$40.30 |
| CTEV | Claritev | $22.87 | -$3.04 | -11.73% | 3.5K | $428M | $12.86$74.07 |
| AXG | Solowin | $3.19 | -$0.42 | -11.53% | 3.4K | $678M | $1.16$5.09 |
| WAT | Waters | $337.78 | -$43.51 | -11.41% | 44.1K | $23B | $275.05$414.15 |
| ASST | Strive Asset Management, Llc | $10.58 | -$1.34 | -11.20% | 1.7M | $397M | $7.73$268.40 |
| ABTS | Abits Group | $3.13 | $0.02 | 0.64% | 741 | $7.4M | $1.35$10.86 |
Related Articles
Featured Article
Hims & Hers Takes On Novo Nordisk: What We Know Right Now
Travis Hoium|Feb 5, 2026
Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.
HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering
Travis Hoium|Feb 4, 2026
Hims & Hers is moving beyond prescriptions to preventative testing.
Stocks to Love in 2026
Motley Fool Staff|Jan 11, 2026
Are you looking for investment opportunities in 2026?
Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip?
Parkev Tatevosian, CFA|Nov 26, 2025
The healthcare industry is ripe for disruption.
Monday.com Stock Is Crashing. Time to Buy the Dip?
Timothy Green|Nov 10, 2025
The software company's slight guidance cut tanked the stock.
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock?
Geoffrey Seiler|Nov 9, 2025
The company continues to have a strong growth outlook ahead.
Hims & Hers Stock Jumps 9% After Huge Announcement
Travis Hoium|Oct 16, 2025
New products are coming to the Hers platform.
1 Growth Stock Down 30% You Don't Want to Miss On
Neil Rozenbaum|Oct 6, 2025
The recent pullback is a blessing in disguise.
Cleveland-Cliffs Stock Just Keeps Dropping. Buying Opportunity, or a Sign to Steer Clear?
Reuben Gregg Brewer|Oct 1, 2025
Cleveland-Cliffs is losing money as the steel industry deals with a downturn, which is exactly why you might want to buy it.
A Healthcare Debate: Progyny vs. Hims & Hers
Motley Fool Staff|Sep 26, 2025
Motley Fool analysts take a look.
